drugset

drugset / Trial / NCT03751761

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

NCT03751761 ↗

Phase 1/2 Completed 58 enrolled Asan Medical Center Hallym University Medical Center · collab Seoul National University Bundang Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate safety and response rate of durvalumab/tremelimumab in combination with paclitaxel in patients with metastatic gastric cancers who fail a first-line chemotherapy

Timeline

Start: 2018-06-11
Primary completion: 2023-08-30
Completion: 2023-08-30

Publications

Lee KW, Zang DY, Kim HD, Kim JW, Kim BJ, Kang YK, Ryu MH, Kim HK. Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer. Br J Cancer. 2025 Aug;133(2):208-215. doi: 10.1038/s41416-025-03052-y. Epub 2025 May 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	1500 mg	—
Subject	Paclitaxel	Small molecule	60 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	80 mg/m2	Intravenous
Subject	Tremelimumab	Monoclonal antibody	75 mg	—

Indications